View all newsletters
Non-Alcoholic Steatohepatitis (NASH) accounted for a 6.3% share of the global clinical trials within the Gastrointestinal therapy area in 2021,…
ByStroke accounted for a 15.1% share of the global clinical trials within the Cardiovascular therapy area in 2021, registering an…
ByRheumatoid Arthritis accounted for a 20.8% share of the global clinical trials within the Immunology therapy area in 2021, registering…
ByOsteoarthritis accounted for a 26.0% share of the global clinical trials within the Musculoskeletal Disorders therapy area in 2021, registering…
ByHepatitis C accounted for a 0.9% share of the global clinical trials within the Infectious Disease therapy area in 2021,…
ByAsthma accounted for an 18.7% share of the global clinical trials within the Respiratory therapy area in 2021, registering a…
ByParkinson's Disease accounted for a 2.8% share of the global clinical trials within the Central Nervous System therapy area in…
ByThe global clinical trials activity saw a decrease of 8.3% in Q1 2022, when compared with the rolling average of…
ByThank you for subscribing to Clinical Trials Arena